Company / Total Debt
Inhibrx Biosciences, Inc. Total Debt History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$100.6M
FY2025
5-year range
$0 / $207.0M
FY2023-FY2025
Trend
-
vs FY2024
Sector context
#58 of 83
Health Care
What the data says
At $101M, Inhibrx Biosciences, Inc.'s total debt ranks #26 of 83 in the Health Care sector. Improved from $207M to $101M over the past 2 years.
Based on SEC 10-K filings.
$101M in FY2025.
Improved from $207M to $101M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#26 of 83 in Health CareTop 30% of 83This company $100.6M Sector average $6.2B
▼
-98.4% below sector average
Key checks
Key Insights
- Ranks #58 out of 83 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $100.6M | - |
| FY2024 | $0 | -100.0% |
| FY2023 | $207.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026